Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Yu-Ge Ran"'
Publikováno v:
Nutrition and Cancer. 75:1233-1242
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e498e51a8803c70a7a6cc8b33b5f9c91
https://doi.org/10.1080/01635581.2023.2186267
https://doi.org/10.1080/01635581.2023.2186267
Publikováno v:
Future Oncology. 17:745-754
Aim: We performed an updated meta-analysis to evaluate the efficacy and safety of lenvatinib in cancer patients. Materials & methods: Databases were searched to identify relevant trials. Data were extracted to evaluate overall survival, progression-f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5d4fd86a766e0dbe5304fd21c2f8874
https://doi.org/10.2217/fon-2020-0327
https://doi.org/10.2217/fon-2020-0327
Publikováno v:
Expert Review of Clinical Pharmacology. 13:311-320
Objective: We performed a meta-analysis to quantify the overall incidence and risk of proteinuria associated with five newly approved VEGFR-TKIs (regorafenib, vandetanib, cabozantinib, lenvatinib, ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eaba57608f9ce0baff42c2d5e5a72e5e
https://doi.org/10.1080/17512433.2020.1734450
https://doi.org/10.1080/17512433.2020.1734450
Publikováno v:
Medicine. 100:e25427
This study aims to establish an effective prognostic nomogram for small cell carcinoma of the esophagus (SCCE).A total of 552 patients with SCCE from 1975 to 2016 were extracted from the surveillance, epidemiology, and end results (SEER) database. A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::90e7b0297199fe8c6f9139c1fdbb36c2
https://doi.org/10.1097/md.0000000000025427
https://doi.org/10.1097/md.0000000000025427
Publikováno v:
Future Oncology. 12:2741-2753
Aim: We performed a meta-analysis to evaluate the incidence and risk factors of severe rash associated with the use of EGFR tyrosine kinase inhibitors (TKIs). Methods: PubMed, EMBASE and oncology conference proceedings were searched for articles publ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75ed3f59bcc2672a90390015a689f412
https://doi.org/10.2217/fon-2016-0180
https://doi.org/10.2217/fon-2016-0180
Publikováno v:
Drug Design, Development and Therapy
Xi Zhang,1 Yuge Ran,1 Kunjie Wang,2 Yuanxue Zhu,2 Jinghua Li3 1Department of Radiation Oncology, 2Department of Medical Oncology, 3Department of Hepatobiliary Surgery, Affiliated Hospital of Hebei University, Baoding, People’s Republic of China Pur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2394d204f397a4a182f4e57a7f5fd5ff
https://doi.org/10.2147/dddt.s115493
https://doi.org/10.2147/dddt.s115493
Autor:
Miaoling Liu, Gui-Min Cui, Shuai Qie, Yu-Ge Ran, Yuan Tian, Xiaojing Sun, Huibin Yang, Chan Liu, Nan Li, Wenfan Sun
Publikováno v:
Medicine
Introduction: At present, there is no uniform consensus on the treatment of brain metastases from esophageal cancer. The studies on the treatment of brain metastases from esophageal cancer by radiotherapy combined with temozolomide (TMZ) are even rar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3eef0e503dfa08c681423a374a0fd9c4
https://doi.org/10.1097/md.0000000000020223
https://doi.org/10.1097/md.0000000000020223
Publikováno v:
British Journal of Clinical Pharmacology. 81:33-40
Aims Aflibercept is an engineered humanized vascular endothelial growth factor (VEGF)-targeted agent. Severe infections are serious adverse event associated with aflibercept. However, the contribution of aflibercept to infection is still unknown. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc53ee13e46274e5808fe28ab87b49f7
https://doi.org/10.1111/bcp.12758
https://doi.org/10.1111/bcp.12758
Publikováno v:
Future oncology (London, England). 12(12)
Background: A meta-analysis of randomized controlled trials was performed to determine the overall risk of noninfectious severe pneumonitis associated with mTOR inhibitors (mTORi) in cancer patients. Materials & methods: PubMed, EMBASE and oncology c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fb7746ef437f3a861062b24f6823b31
https://pubmed.ncbi.nlm.nih.gov/27067269
https://pubmed.ncbi.nlm.nih.gov/27067269
Publikováno v:
Medicine
Rationale: Extramedullary plasmacytomas (EMPs) are rare solitary soft tissue tumors characterized by monoclonal proliferation of plasma cells. Most lesions occur in the head and neck, but primary tracheal lesions are very rare. Patient Concerns: In t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::946dd45eb3cfe6872f606c9fd8d0d488
https://doi.org/10.1097/md.0000000000009594
https://doi.org/10.1097/md.0000000000009594